$5M financing round led by Kizoo Technology Capital
Fresh capital to be employed for productization, to prepare a clinical trial in organ transplantation and to expand cellvie s pipeline into rejuvenation therapies
Promising initial clinical data generated at Boston Children s Hospital to be published in the Journal of Thoracic and Cardiovascular Surgery
Zurich/Switzerland and Houston/USA, January 25, 2021: cellvie Inc., the leader in Therapeutic Mitochondria Transfer (TMT) and a Harvard University spin-off, closes a $5M round to advance its product pipeline, including a first application in rejuvenation.
Mitochondria are intimately tied to the origin of complex life, the energy of the young and the decline of the old. They are the powerhouses of the cell, generating most of the cellular energy and operate as critical intra-cellular communication nodes. Mitochondria dysfunction has been tied to a host of diseases, ranging from neurodegenerative ailments such as Parkinson s and